Recent Updates
Recently added Catalysts

LY3954068

Phase 1

Alzheimer Disease | Small Molecules | Neurology |Eli Lilly and Company|Trials Updated: Oct 29, 2026

LY3954068 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Mar 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment56

FDA Designations

No designations recorded

LY3954068 clinical trials

LY3954068 · 1 trial · 1 indication

Phase 1 1
NCT06297590A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's DiseaseAlzheimer Disease
RECRUITING56 Analytics
PHASE1RECRUITING
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
Alzheimer DiseaseUnlock trial analytics

Study Endpoints

Primary Endpoints

Part A: Number of participants with one or more Adverse Event (s) (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration
Baseline up to Week 36 and Week 72 (for optional bridging period participants)

A summary of AEs, TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module

Part B: Number of participants with one or more Adverse Event (s) (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration
Baseline up to Week 76

A summary of AEs, TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module

Secondary Endpoints

Part A: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax)
Day 1 up to Week 36
Part B: PK: Cmax
Day -1 up to Week 76
Part A: PK: Area Under the Concentration Versus Time Curve (AUC)
Day 1 up to Week 36
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
LY3954068 (Part A)EXPERIMENTALSingle ascending dose of LY3954068 administered intrathecally (IT)
Placebo (Part A)PLACEBO_COMPARATORSingle ascending dose of placebo administered IT
LY3954068 (Part B)EXPERIMENTALMultiple ascending dose of LY3954068 administered IT
Placebo (Part B)PLACEBO_COMPARATORMultiple ascending dose of placebo administered IT

Interventions

NameTypeDescription
LY3954068DRUGAdministered IT
PlaceboDRUGAdministered IT
Flortaucipir F18DRUGAdministered intravenously (IV) prior to Positron Emission Tomography (PET) scan
Unlock Study Design Details

Eligibility Criteria

Age Range50 Years to 85 Years
SexALL
Healthy VolunteersNo
Study Sites10

Inclusion Criteria: * Have a body mass index (BMI) within the range 18 to 40 kilograms per square meter (kg/m²), inclusive, at screening. * Have gradual and progressive change in memory function for greater than or equal to (≥) 6 months as reported by the participant or informant. * Have a mini men...

Countries:United StatesJapanUnited Kingdom
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMOct 29, 2026NCT06297590Enrollment: 48 → 56
MEDIUMOct 29, 2026NCT06297590Enrollment: 48 → 56
LOWAug 24, 2026NCT06297590lastUpdatePostDate: changed
LOWAug 24, 2026NCT06297590lastUpdatePostDate: changed

Frequently asked questions about LY3954068

What is LY3954068?

LY3954068 is an investigational small molecule drug being developed by Eli Lilly and Company for Alzheimer disease. It is in Phase 1 clinical development and is being studied in participants with early symptomatic Alzheimer disease. LY3954068 has not been approved by the FDA and remains in clinical testing.

What is LY3954068 used for in Alzheimer disease?

LY3954068 is being studied as a treatment for early symptomatic Alzheimer disease. Its only disclosed clinical trial enrolls participants aged 50 years and older with early symptomatic Alzheimer disease, and it is not being tested in healthy volunteers. The drug is investigational and has not been approved for any use.

Who makes LY3954068?

LY3954068 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the first-in-human Phase 1 study of the drug in early symptomatic Alzheimer disease.

What phase is LY3954068 in?

LY3954068 is in Phase 1 clinical development. Its single trial is a first-in-human Phase 1 study that is currently recruiting. The drug is investigational, and no Phase 2 or later-stage trials have been completed.

What clinical trials is LY3954068 in?

LY3954068 is being studied in one clinical trial, NCT06297590, titled a first-in-human study of LY3954068 in participants with early symptomatic Alzheimer's disease. The Phase 1 trial is recruiting 56 participants across the United States, Japan, and the United Kingdom, and it is randomized, double-blind, and placebo-controlled.

Is LY3954068 FDA approved?

No. LY3954068 is an investigational drug in Phase 1 clinical development and has not been approved by the FDA. It is being evaluated in a single first-in-human study in early symptomatic Alzheimer disease, and its safety and efficacy have not been established.